SEC Form 4	
------------	--

 $\Box$ 

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01 300	2001 30(11) 0	i uic i	Incouncil		iipaily Act c	1 1340							
1. Name and Address of Reporting Person <sup>*</sup> Babu Yarlagadda S				I	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle)						BCRX ]							Officer ( below)	give title		Other (sp elow)	ecify	
4505 EMPEROR BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 12/15/2020								Senior VP - Drug Discovery					
SUITE 200					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) DURHA	M N	IC	27703									X	Form file	ed by One R	Reporting	Person		
			2//00										Form file Person	ed by More 1	than One	Reporti	ng	
(City)	(5	State)	(Zip)															
		T	able I - Non-	Derivat	ive S	ecurities	Acc	quired,	Dis	posed of	f, or Ber	neficially	Owned					
Date				2. Transact Date (Month/Day	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			d (A) or r. 3, 4 and 5]	Beneficial Owned Fo	F Iy (	6. Owners Form: Dire D) or Indi I) (Instr. 4	ect li rect B ) C	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 au				nstr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Execution (Month/Day/Year) if any	3A. Deemed Execution Date if any (Month/Day/Yea	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ow For Dir or I (I) (	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	((5)			
Emp. Stock Option (Right to Buy)	\$8.31	12/15/2020		A		280,000 <sup>(1)</sup>		12/15/20	21	12/15/2030	Common Stock	280,000	\$0	280,000	)	D		

Explanation of Responses:

1. Annual Employee Option Grant becomes exercisable at the rate of 25% of each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of 12/17/2020

 attorney
 \*\* Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.